Read by QxMD icon Read

Erectil dysfunction

Mohammed A Said, Akanksha Mehta
PURPOSE OF REVIEW: Male pattern hair loss, mediated by dihydrotestosterone, is a common hair loss disorder, affecting over 50% of men over the age of 50. The 5-α reductase inhibitors, finasteride and dutasteride, are Food and Drug Administration-approved drugs for the treatment of this disorder. Several recent studies have reported adverse sexual and spermatogenic events among young men using 5-α reductase inhibitors, such as erectile dysfunction, decreased ejaculate volume, decreased libido, and infertility...
June 16, 2018: Current Urology Reports
Luca Loprete, Chiara Leuratti, Valeria Frangione, Milko Radicioni
BACKGROUND: Sildenafil was the first selective drug available on the market as oral therapy for erectile dysfunction (ED). A novel sildenafil orodispersible film (ODF) for ED treatment, containing sildenafil citrate, has recently been marketed. OBJECTIVES: Study objective was to investigate sildenafil bioavailability of the novel ODF formulation after sublingual and supralingual administration. METHODS: In this randomised, two-way cross-over study, 12 healthy male volunteers received a single 50 mg sildenafil dose by the sublingual and supralingual administration routes...
June 16, 2018: Clinical Drug Investigation
Kevin Wymer, Matthew Ziegelmann, Joshua Savage, Tobias Kohler, Landon Trost
OBJECTIVE: To compare outcomes of men with or without calcified plaques undergoing collagenase clostridium histolyticum (CCH) injections for Peyronie's Disease (PD) and identify predictors of CCH success. MATERIAL AND METHODS: From March 2014 through January 2017, data were prospectively collected on 192 patients who underwent 1-4 cycles of CCH for the treatment of PD. Of these, 115 completed ≥2 CCH cycles and had data on curvature assessment. The primary outcome was the percentage of men with >20% improvement in composite curvature...
June 14, 2018: Urology
Mathew Wooster, Paul Armstrong, Martin Back
OBJECTIVE: Maintenance of pelvic circulation has been connected to reduced risks of ischemic colitis, buttock claudication, erectile dysfunction, and spinal cord ischemia during the treatment of extensive aorto-iliac aneurysmal disease. We evaluate the mid to late follow up of a cohort of patients treated using one preservation technique, the endovascular external (EIA) to internal (IIA) iliac artery bypass. METHODS: All patients undergoing elective retrograde EIA-IIA endovascular bypass at a single institution were retrospectively reviewed over a ten-year period from 2006-2016...
June 13, 2018: Annals of Vascular Surgery
Tao Zheng, Tian-Biao Zhang, Chao-Liang Wang, Wei-Xing Zhang, Dong-Hui Jia, Fan Yang, Yang-Yang Sun, Xiao-Ju Ding, Rui Wang
Icariside II (ICA II) is used in erectile dysfunction treatment. Adipose tissue-derived stem cells (ADSCs) are efficient at improving erectile function. This study aimed to explore the action mechanism of ADSCs in improving erectile function. ADSCs were isolated from the adipose tissues of rats. Cell proliferation was determined using the Cell Counting Kit-8 (CCK-8) assay. The expressions of mRNA and protein were determined separately through qRT-PCR and western blot. The endogenous expressions of related genes were regulated using recombinant plasmids and cell transfection...
June 14, 2018: Molecules and Cells
N D Akhvlediani, I P Matyukhov
Sildenafil is the first phosphodiesterase type 5 inhibitor (PDE-5), used in the management of erectile dysfunction (ED). The effectiveness and safety of the original drug have been studied most extensively among ED medications. Sildenafil has been successfully used for ED of different etiology and severity. To date, this PDE-5 remains the drug of choice for many patients with erectile dysfunction.
May 2018: Urologii︠a︡
E A Efremov, E V Kasatonova, Ya I Mel'nik, A A Nikushina
Erectile dysfunction (ED) has a significant negative impact on the quality of life of the patients and their partners. The sequence and regimens of ED therapy have become quite evident since the advent of phosphodiesterase type 5 inhibitors (PDE-5). However, there have been continued basic research of the efficacy and safety of these agents and studies aimed at new therapeutic goals. In recent years, the attention of researchers has shifted into a wider range of issues related to the personalized PDE-5 therapy, including sexual satisfaction, psychosocial variables (e...
May 2018: Urologii︠a︡
E V Shpot, D V Chinenov, A V Amosov, Ya N Chernov, M V Yurova, Yu V Lerner
RELEVANCE: Erectile dysfunction (ED) associated with radical prostatectomy (RP) affects 25-75% of patients and has a significant negative impact on their quality of life AIM: To analyze the maintenance of erectile function after RP depending on the type of endoscopic access and nerve-sparing. MATERIALS AND METHODS: This retrospective study comprised 231 patients with localized prostate cancer, who underwent surgery between February 2015 and February 2016. Surgery was performed using one of three approaches: laparoscopic, extraperitoneoscopic or robot-assisted...
May 2018: Urologii︠a︡
L G Spivak, D V Platonova, D V Enikeev, L M Rapoport, A Z Vinarov, Yu L Demidko
RELEVANCE: Erectile dysfunction (ED) is a common condition. Pharmacological management of ED involves medications produced by chemical synthesis. Despite high efficiency, their use is often accompanied by some side effects. Considering this, herbal preparations with sufficient efficacy and greater safety have received much attention. AIM: To compare the efficacy and safety of two herbal preparations (EFFEX Tribulus and Tribestan) based on Tribulus Terrestris herb dry extract in patients with ED...
May 2018: Urologii︠a︡
Khushabu Kasabwala, Gilbert J Wise
INTRODUCTION: Each year, varicella-zoster virus (VZV) affects nearly one million people in the United States, often in the form of herpes zoster, or shingles. The urologic system is a rare but often debilitating target. This paper reviews the epidemiology, symptomatology, diagnosis, and management of VZV as it relates to urologic practice. MATERIALS AND METHODS: We performed a PubMed search using the query "herpes zoster" and "varicella-zoster virus" combined with multiple urological terms...
June 2018: Canadian Journal of Urology
Adam J Singer, Henry Towery, Steve A McClain
OBJECTIVES: A major goal of burn management is to reduce the progression of necrosis in the zone of ischemia surrounding the central zone of necrosis. A rat comb burn model is often used to assess the progression of necrosis in the zone of ischemia. We compared various combinations of naproxen [NPX], N-acetyl cysteine [NAC], and tadalafil [TD] (a phosphodiesterase-5 inhibitor used as a vasodilator to treat erectile dysfunction) in a rat comb burn model to determine their effects on injury progression...
June 9, 2018: Burns: Journal of the International Society for Burn Injuries
Tao Wang, Li Zhuan, Zhuo Liu, Ming-Chao Li, Jun Yang, Shao-Gang Wang, Ji-Hong Liu, Qing Ling, Wei-Min Yang, Zhang-Qun Ye
Background: Currently available evaluation criteria for penile tumescence and rigidity have been fraught with controversy. In this study, we sought to establish normative Chinese evaluation criteria for penile tumescence and rigidity by utilizing audiovisual sexual stimulation and RigiScan™ test (AVSS-Rigiscan test) with the administration of phosphodiesterase-5 inhibitor. Methods: A total of 1169 patients (aged 18-67 years) complained of erectile dysfunction (ED) underwent AVSS-RigiScan test with the administration of phosphodiesterase-5 inhibitor...
June 20, 2018: Chinese Medical Journal
Marcello H A Da Silva, Waldemar S Costa, Francisco J B Sampaio, Diogo B De Souza
Erectile dysfunction is a common side effect of finasteride and dutasteride treatments. The objective of this study was to investigate the structural changes in the penis using a benign prostatic hyperplasia (BPH) rodent model treated with dutasteride or finasteride. Sixty male rats were divided into the following groups: C, untreated control rats; C + D, control rats receiving dutasteride; C + F, control rats receiving finasteride; H, untreated spontaneously hypertensive rats (SHRs); H + D, SHRs treated with dutasteride; and H + F, SHRs treated with finasteride...
June 8, 2018: Asian Journal of Andrology
Abdalla M Etabbal, Fathi F Hussain, Mohamed O Benkhadoura, Abdalla M Banni
Objective: To report on our initial experience in the management of war-related penile injuries; proper diagnosis and immediate treatment of penile injuries is essential to gain satisfactory results. Besides treating primary wounds and restoring penile function, the cosmetic result is also an important issue for the surgeon. Patients and methods: The study was conducted in the Department of Urology at Benghazi Medical Center and comprised all patients who presented with a shotgun, gunshot or explosive penile injury between February 2011 and August 2017...
June 2018: Arab Journal of Urology
S M Iftekhar Uddin, Mohammadhassan Mirbolouk, Zeina Dardari, David I Feldman, Miguel Cainzos-Achirica, Andrew P DeFilippis, Philip Greenland, Ron Blankstein, Kevin L Billups, Martin Miner, Khurram Nasir, Michael J Blaha
Vascular erectile dysfunction (ED) and cardiovascular disease (CVD) share common risk factors including obesity, hypertension, metabolic syndrome, diabetes mellitus, and smoking. ED and CVD also have common underlying pathological mechanisms, including endothelial dysfunction, inflammation, and atherosclerosis.1 Despite these close relationships, the evidence documenting ED as an independent predictor of future CVD events is limited.We therefore leveraged the MESA study (Multi-Ethnic Study of Atherosclerosis), an ethnically diverse, community-based, multisite prospective cohort study, to examine the value of self-reported ED for predicting incident coronary heart disease (CHD) and CVD in those free of these CVD events at baseline...
June 11, 2018: Circulation
Serkan Karakus, Biljana Musicki, Arthur L Burnett
OBJECTIVES: To clarify the molecular basis of penile erection at the human level and distinguish mechanisms underlying vasculogenic and post-radical prostatectomy (post-RP) erectile dysfunction (ED) subtypes. PATIENTS AND METHODS: Erectile tissue was obtained from men without histories of ED who underwent penile surgery for Peyronie's disease (control, n=5) and with ED who underwent penile prosthesis implantation (n=17). ED was categorized into vasculogenic (n=8) and post-RP (n=9) subtypes...
June 11, 2018: BJU International
Jon Montgomery, Cathaleen Madsen, Todd Leroux, Tracey Pérez Koehlmoos
Phosphodiesterase-5 inhibitors (PDE-5Is) are the first-line medical treatments for erectile dysfunction (ED), but are often restricted in public formularies. This study assesses PDE-5I usage among active-duty service members before and after the addition of sildenafil to the formulary of the Military Health System (MHS) in 2012. To assess, a cross-sectional evaluation was conducted, utilizing encounter and pharmaceutical claims data from the Military Health System Data Repository between 2010 and 2014. Separate zero-inflated, negative binomial models were used to assess changes in usage rates by prescription and by number of pills issued, for 37 947 patients...
June 11, 2018: International Journal of Impotence Research
J F Mao, X Wang, B Q Yu, Y J Gao, M Nie, X Y Wu
Objective: To investigate the clinical features and management of male patients with adult-onset idiopathic hypogonadotropic hypogonadism (AIHH). Methods: Clinical features and treatment of six patients with AIHH between January 2010 and June 2017 were retrospectively reviewed. Results: The patients were all male, with an age of 26 (20-35) years old and they experienced complete pubertal development. The main complaints were decreased libido, erectile dysfunction and gynecomastia. Physical examination found that the testicular size was 15 (12-20) ml and they were fully virilized...
May 29, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Bing Liu, Linxin Zhu, Jingxiang Zhong, Guohua Zeng, Tuo Deng
INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line drugs for erectile dysfunction. Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked with PDE5-I use. However, no meta-analysis or conclusive review has explored the association between NAION and PDE5-I use. AIM: To investigate the association between PDE5-I use and risk of NAION. METHODS: A comprehensive literature search was conducted using online databases in October 2017 to obtain studies researching the association between PDE5-I application and occurrence of NAION...
June 5, 2018: Sexual Medicine
Eugene Shkolyar, Shufeng Li, Jean Tang, Michael L Eisenberg
BACKGROUND: Phosphodiesterase type 5 inhibitors (PDE5is), a treatment for erectile dysfunction, pulmonary hypertension (pHTN), and lower urinary tract symptoms (LUTS), have been implicated in melanoma development. AIM: We sought to determine the association between PDE5i use and melanoma development among patients with erectile dysfunction, pHTN, and LUTS. METHODS: This was a retrospective cohort study of subjects contained within the Truven Health MarketScan claims database, which provides information on insurance claims in the United States for privately insured individuals, from 2007-2015...
June 5, 2018: Journal of Sexual Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"